CL2012000580A1 - Composicion para generar respuesta inmune especifica de antigeno que comprende un virus de la lengua azul; kit para generar respuesta especifica de antigeno. - Google Patents

Composicion para generar respuesta inmune especifica de antigeno que comprende un virus de la lengua azul; kit para generar respuesta especifica de antigeno.

Info

Publication number
CL2012000580A1
CL2012000580A1 CL2012000580A CL2012000580A CL2012000580A1 CL 2012000580 A1 CL2012000580 A1 CL 2012000580A1 CL 2012000580 A CL2012000580 A CL 2012000580A CL 2012000580 A CL2012000580 A CL 2012000580A CL 2012000580 A1 CL2012000580 A1 CL 2012000580A1
Authority
CL
Chile
Prior art keywords
antigen
response
kit
composition
specific
Prior art date
Application number
CL2012000580A
Other languages
English (en)
Inventor
David James Bartram
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42829427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000580(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CL2012000580A1 publication Critical patent/CL2012000580A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composición para generar respuesta inmune específica de antígeno que comprende un virus de la lengua azul; kit para generar respuesta específica de antígeno.
CL2012000580A 2009-09-02 2012-03-02 Composicion para generar respuesta inmune especifica de antigeno que comprende un virus de la lengua azul; kit para generar respuesta especifica de antigeno. CL2012000580A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23912509P 2009-09-02 2009-09-02

Publications (1)

Publication Number Publication Date
CL2012000580A1 true CL2012000580A1 (es) 2012-07-13

Family

ID=42829427

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000580A CL2012000580A1 (es) 2009-09-02 2012-03-02 Composicion para generar respuesta inmune especifica de antigeno que comprende un virus de la lengua azul; kit para generar respuesta especifica de antigeno.

Country Status (17)

Country Link
US (1) US20110110980A1 (es)
EP (1) EP2473190A1 (es)
JP (1) JP2013503869A (es)
KR (1) KR20120062853A (es)
CN (1) CN102481358A (es)
AR (1) AR078147A1 (es)
AU (1) AU2010289734A1 (es)
BR (1) BR112012004703A2 (es)
CA (1) CA2770070A1 (es)
CL (1) CL2012000580A1 (es)
CO (1) CO6511241A2 (es)
MX (1) MX2012002630A (es)
RU (1) RU2012107823A (es)
TW (1) TW201125579A (es)
UY (1) UY32876A (es)
WO (1) WO2011028652A1 (es)
ZA (1) ZA201200892B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103305471B (zh) * 2013-06-18 2014-11-05 中国农业科学院哈尔滨兽医研究所 抗蓝舌病病毒血清8型vp2蛋白的单克隆抗体btv8-vp2-4d9及其识别的b细胞表位多肽和应用
CN112870346A (zh) * 2021-01-21 2021-06-01 云南省畜牧兽医科学院 一种蓝舌病病毒二价灭活疫苗的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4567043A (en) * 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
CA2302522C (en) 1997-08-29 2010-08-17 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus

Also Published As

Publication number Publication date
KR20120062853A (ko) 2012-06-14
MX2012002630A (es) 2012-05-08
JP2013503869A (ja) 2013-02-04
BR112012004703A2 (pt) 2016-04-12
TW201125579A (en) 2011-08-01
RU2012107823A (ru) 2013-10-10
CN102481358A (zh) 2012-05-30
UY32876A (es) 2011-04-29
CO6511241A2 (es) 2012-08-31
CA2770070A1 (en) 2011-03-10
AR078147A1 (es) 2011-10-19
US20110110980A1 (en) 2011-05-12
ZA201200892B (en) 2012-10-31
EP2473190A1 (en) 2012-07-11
WO2011028652A1 (en) 2011-03-10
AU2010289734A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CO7111273A2 (es) Anticuerpos cd47 y métodos de uso de los mismos
TWD159372S (zh) 防爆ｌｅｄ燈具之部分
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
UY34411A (es) Inmunoenlazantes dirigidos contra esclerostina
CL2012002011A1 (es) Metodo para proporcionar informacion a un usuario sobre capsulas para preparacion de bebida que usa codigo.
UY34404A (es) Anticuerpo estable unido a múltiples antígenos
GB201112048D0 (en) Orbiting wavelength conversion element
UY34343A (es) Proteinas de unión al antígeno cd27l
BR112012031120A2 (pt) sistema de conversão de energia cinética rotacional
EA201390613A1 (ru) Обогащенный дейтерием расагилин
TWD160355S (zh) 照明設備
TWD158475S (zh) 發光二極體燈具之部分（衍生一）
CY1118539T1 (el) Ανασυνδυασμενο μυκοβακτηριο ως εμβολιο
CL2011002403S1 (es) Luminaria solar.
BR112013007514A2 (pt) anticorpo isolado, uso da composição e método
FI20100337A0 (fi) Laite energian tuottamiseksi vesivoiman avulla
CL2011000262A1 (es) Virus de bronquitis infecciosa (bi) derivado de un virus similar a qx-bi; composicion de vacuna que comprende dicho virus; procedimiento para preparar dicho virus.
ES2572368T3 (es) Tratamiento de la artrosis
CL2012002246A1 (es) Proceso para producir un extracto de alergenos; extracto de alergenos; uso de un extracto de alergenos para tratar alergia a los cacahuetes; composicion farmacéutica que comprende dicho extracto; vacuna que comprende un extracto de alergenos.
CL2012000580A1 (es) Composicion para generar respuesta inmune especifica de antigeno que comprende un virus de la lengua azul; kit para generar respuesta especifica de antigeno.
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
ATE539087T1 (de) Preprocalcitonin-antigen-t-epitope